Alpha Teknova, Inc. (TKNO) stock
TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30145% above fair value
$8.21−0.08 (-1.02%)
Close on Nov 13, 2026Market cap $440.78MP/E –Yield –
Alpha Teknova price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Alpha Teknova's price to sales ratio was 10.6× on Nov 11, 2026, against 6.3× a year earlier. Over the last 5 years it ranged from 1.3× to 15.5×, with a median of 5.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 10.6× | +5.5 |
| 2025 | Dec 31, 2025 | 5.1× | −7.1 |
| 2024 | Dec 31, 2024 | 12.2× | +8.1 |
| 2023 | Dec 29, 2023 | 4.1× | +0.5 |
| 2022 | Dec 30, 2022 | 3.6× | −11.9 |
| 2021 | Dec 31, 2021 | 15.5× | – |
See a number that looks wrong?